Aim: To discuss commonly encountered diagnostic and therapeutic dilemmas in pediatric obstructive sleep apnea (OSA).
INTRODUCTION
Obstructive sleep apnea (OSA) is a relatively common pediatric disorder and is associated with adverse health consequences including neurocognitive and behavioral problems, cardiovascular complications including systemic and pulmonary hypertension, and impaired growth. 1 Although recent clinical practice guidelines have been published by both the American Academy of Pediatrics (AAP) and the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) guidelines, an evidence gap still exists to direct appropriate diagnosis and treatment. In this article we discuss selected commonly encountered controversies in the diagnosis and management of pediatric OSA.
DIAGNOSTIC DILEMMAS

To make the Diagnoses of OSA, does One require a Sleep Study? Yes
The International Classification of Sleep Disorders-3rd edition states that one must have an abnormal sleep study in combination with either nighttime or daytime symptoms. Nighttime symptoms may include habitual snoring, witnessed apneas, mouth breathing, sweating during sleep, restless sleep, nocturnal enuresis (secondary), sleepwalking, night terrors, and neck hyperextension. Daytime symptoms include daytime sleepiness, hyperactivity, poor school performance, inattention or impaired concentration, aggressive behavior, difficulty waking in the morning, and headaches that are worse in the morning. 
Can a Child meet the AASM
Does Tonsil Size matter? Yes and No
One is more confident that a child may have SDB secondary to the tonsils when they are hypertrophic (3+ to 4+), although previous studies have demonstrated a weak relationship between tonsil size and OSA severity. The questionable importance of tonsil size is further highlighted in the Childhood Adenotonsillectomy Trial (CHAT) study since the qualification for study entry required the presence of a visible tonsil (1+) not one that was hypertrophied.
Can a Child have a "Normal Sleep Study" but still benefit from Intervention?
The clinical significance of primary snoring vs OSA is one issue at the core of the controversy related to the appropriate role of preoperative PSG in the otherwise healthy child with clinical SDB and tonsillar hypertrophy. Preoperative PSG is able to differentiate children who are primary snorers from those with OSA. Whether or not this distinction is clinically important depends on differences in associated morbidity and response to therapy. Some previous studies have demonstrated neurobehavioral deficits in children with primary snoring, and there is no clear dose response between degree of OSA and neurocognitive impairment. 3 In addition, children with primary snoring have been found to clinically benefit from tonsillectomy and adenoidectomy (T&A) compared with observation. 4 These previous findings are bolstered by recent results from the CHAT study, in which there was a mild, if any, relationship between OSA severity as assessed by PSG and baseline morbidity or response to T&A. 5, 6 Currently, the Pediatric Adenotonsillectomy Trial for Snoring (PATS) is recruiting participants with primary snoring to be randomized to either T&A or watchful waiting, and will provide more outcomes data to inform this discussion. There are also several alternative devices under investigation for the diagnosis of OSA in children. Overnight pulse oximetry has been used for years, and a classification system has been developed according to the McGill Score. 9 While an abnormal nocturnal oximetry study does provide good positive predictive value in the appropriate clinical context, the reliance on only a single channel results in low negative predictive value and cannot delineate respiratory events, in contrast to standard PSG. Home sleep studies with many or all of the same sensors included as in-lab PSG are also being investigated. Some studies have demonstrated adequate technical feasibility in children, although this is currently in the investigational phase. 10 Finally, a recent device, named the Sonomat, has been under investigation. This is a contactless monitoring system that records body movements, breathing movements, and breath and heart sounds from a series of vibration and sound sensors embedded in a mat that the patient sleeps on in their home setting; an initial validation study in adults has yielded encouraging results.
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What is the Role of Preoperative PSG?
The appropriate role of preoperative PSG remains controversial. Currently, both the AAP and the AASM advocate for routine preoperative PSG in the child with suspected OSA in order to confirm the diagnosis prior to surgery. 1 This recommendation is based primarily on the knowledge that history and physical examination alone do not consistently predict the presence or severity of OSA based on conventional PSG metrics. In contrast, the AAO-HNS advocates for the use of preoperative PSG in children with significant comorbidities or those with discrepancy between tonsil size on examination and reported history, 12 and recommends PSG in children at higher risk of perioperative complications. In our opinion, it makes sense to perform preoperative PSG when the child is at a higher perioperative risk, when T&A is unlikely to be curative, when parents request objective diagnosis prior to surgery, or when history and examination are inconsistent. One argument in favor of preoperative PSG is that it can differentiate mild from moderate/severe OSA. This distinction may be clinically useful because children with mild OSA may be candidates for medical therapy with intranasal steroids and/or leukotriene inhibitor rather than surgery. There is evidence from randomized clinical trials demonstrating that children with nonsevere OSA benefit from medical therapy. [13] [14] [15] [16] Therefore, preoperative PSG may identify children with nonsevere OSA who are candidates for medical, rather than surgical, therapy.
CHALLENGES IN MANAGEMENT Surgical Cure
Adenotonsillectomy is considered first-line therapy for OSA in children. When discussing treatment options in the clinical setting, families naturally are interested in cure rates of T&A vs other treatment options. Unfortunately, the answer depends on how cure is defined and on patient characteristics. Results from CHAT suggest normalization of PSG (defined by OAHI < 2/hour) in 79% of children at 7 months after T&A; children with severe OSA or major comorbidities were not included in this study. 17 A meta-analysis of over a thousand children demonstrated normalization of PSG (defined by AHI < 1) in 74% of uncomplicated patients 18 ;
in contrast, the same meta-analysis demonstrated that children with selected characteristics (severe obesity, severe baseline OSA, younger) had substantially lower rates of normalization on PSG, at 38%. A multicenter trial demonstrated a similar pattern, with normalization of PSG significantly affected by baseline factors including age, obesity, comorbid respiratory disease, and severity of baseline OSA. 19 Children with Down syndrome and craniofacial anomalies are also at increased risk for persistent OSA following T&A. Cure rates also vary depending on the outcome of interest. Various definitions of PSG normalization have been used in previous studies (e.g., OAHI < 1, < 2, < 5/ hour). Furthermore, cure should not just be limited to PSG results, but also clinical symptoms. This was best illustrated by the watchful waiting arm of the CHAT trial, in which 42% of children had spontaneous normalization of their PSG, but only 15% of children had symptomatic resolution. 20 Given the nuances delineated above, an accurate and understandable answer for parents inquiring regarding cure rates would be that T&A is curative in the majority of healthy children with nonsevere disease; in contrast, while children with obesity, severe baseline disease, or other selected comorbidities usually have a meaningful reduction in the severity of OSA, surgical cure is typically not achieved with T&A alone.
Positive Airway Pressure
While T&A is generally effective, there are several additional established and emerging treatment options for OSA in children. Positive airway pressure (PAP) is typically employed when children with moderate to severe OSA are not good surgical candidates, if the family prefers a nonsurgical option, or for residual disease following T&A. If tolerated by the child, PAP is generally very effective at relieving upper airway obstruction and treating OSA. 21 There has never been a sham-controlled randomized trial for PAP in children. A single randomized trial comparing PAP with T&A was performed in a sample of children with either Down syndrome or mucopolysaccharidosis; results demonstrated substantial improvement in both groups from baseline, but no significant between-group differences at 12 months follow-up with respect to AHI, Epworth Sleepiness Scale, or OSA-18. 22 Although PAP devices are only approved for those children who weigh at least 30 kg, they are clinically used in children below that weight if tolerated. While PAP is generally safe with few complications, inappropriate mask fit may result in skin irritation. In addition, long-term use may alter midface development and lead to hypoplasia. Efficacy is limited by child adherence, which may be a significant barrier, especially in children with neurodevelopmental or sensory disorders. In such circumstances, desensitization performed by a behavioral professional can be helpful. For children with respiratory compromise following a T&A, PAP in the immediate postoperative period is a management option, although there may be theoretical risk of subcutaneous emphysema. 23 Finally, although auto-titrating PAP (APAP) is commonly used in adults with OSA, it is not standard practice in children. Preliminary evidence suggests that APAP does not provide optimal continuous positive airway pressure (CPAP) pressure compared with in-lab determined CPAP in children 24 ; we speculate that this is related to the APAP algorithms being based on respiratory events in adults.
Alternate Therapies
Watchful waiting is an option in children with nonsevere OSA is and mild clinical sequelae. Results from CHAT are informative regarding this approach, as 42% of the watchful waiting arm experienced normalization of PSG but only a small minority had symptom resolution. In clinical practice, by the time children are referred to sleep or otolaryngology providers for OSA management, they are often experiencing bothersome symptoms. In ambiguous cases, it may be helpful to utilize a standardized instrument such as the OSA-18 or the Sleep-Related Breathing Disorder subscale of the Pediatric Sleep Questionnaire to assess for OSA-related symptoms and quality of life.
ijhns Several therapies may also be employed as alternatives or in addition to traditional approaches. As discussed above, intranasal steroids and/or leukotriene inhibitor may be considered in nonsevere cases. Orthodontic treatment with rapid maxillary expansion can be beneficial in children with high arched palate by widening the palate and optimizing the nasal airway; importantly, this should be performed prior to puberty when the sutures fuse. Excessive weight may contribute to OSA severity, and weight loss in obese or overweight children may lessen disease severity. If a child's OSA is substantially worse in the supine position, positional therapy may be considered; several devices are commercially available. Myofascial reeducation, which consists of exercises that strengthen the tongue and facial muscles, has been shown to decrease residual OSA following T&A. 25 While all of these approaches show promise, there is currently no standardized approach to their implementation. A practical algorithm which includes some of these approaches in conjunction with conventional therapies has been proposed by Kaditis et al 26 based on PSG findings, clinical sequelae, and patient characteristics.
CONCLUSION
There have been major advancements in the diagnosis and management of OSA in children over the last decade. Clear milestones include the AASM providing standardized scoring and diagnostic criteria for PSG diagnosis of OSA specific to children, the first randomized controlled trial of T&A for OSA in children, and the development of effective treatments beyond T&A. The field will benefit from continued efforts to develop improved metrics and devices for OSA diagnosis, define appropriate treatment of primary snoring, and delineate optimal therapeutic pathways for special populations.
